Skip to main content
Amir  A. Jazaeri, MD, Obstetrics & Gynecology, Houston, TX

Amir A.JazaeriMDFACS, FACOG

Obstetrics & Gynecology Houston, TX

Gynecologic Oncology

Vice Chair for Clinical Research and Director of the Gynecologic Cancer Immunotherapy Program Department of Gynecologic Oncology & Reproductive Medicine University of Texas MD Anderson Cancer Center Vice chair for clinical research

Dr. Jazaeri is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Jazaeri's full profile

Already have an account?

  • Office

    1515 Holcombe Blvd
    Houston, TX 77030
    Phone+1 713-792-6161

Education & Training

  • University of Texas M D Anderson Cancer Center
    University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology, 2000 - 2004
  • University of Virginia Medical Center
    University of Virginia Medical CenterResidency, Obstetrics and Gynecology, 1996 - 2000
  • University of Virginia School of Medicine
    University of Virginia School of MedicineClass of 1996

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2024 - Present
  • TN State Medical License
    TN State Medical License 2024 - 2027
  • GA State Medical License
    GA State Medical License 2024 - 2026
  • TX State Medical License
    TX State Medical License 2002 - 2026
  • AZ State Medical License
    AZ State Medical License 2024 - 2025
  • LA State Medical License
    LA State Medical License 2024 - 2025
  • MS State Medical License
    MS State Medical License 2024 - 2025
  • American Board of Obstetrics and Gynecology Obstetrics & Gynecology
  • American Board of Obstetrics and Gynecology Gynecologic Oncology
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical c... 
    2019 ASCO Annual Meeting - 6/1/2019
  • A phase 2, multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or pe... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

  • UPDATE - IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
    UPDATE - IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive ManagementSeptember 10th, 2024
  • IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
    IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive ManagementSeptember 9th, 2024
  • Immunotherapy Clinical Trial Allows Cervical Cancer Survivor to Thrive
    Immunotherapy Clinical Trial Allows Cervical Cancer Survivor to ThriveAugust 8th, 2024

Professional Memberships